(MENAFNEditorial) iCrowdNewswire - Jul 26, 2017 NewBridge Pharmaceuticals
Dubai Internet City, Dubai, United Arab Emirates
Biotechnology
Newbridge Pharmaceuticals, a pharmaceutical, biologics, and medical device company, engages in the sale and marketing of healthcare products. It offers oncology and supportive care products, such as CLASTEON, a bisphosphonate, which treats problems associated with bone metastasis; SANCUSO, a granisetron transdermal system for the prevention of chemotherapy induced nausea and vomiting; and GLICONORM, a film-coated divisible tablet for the treatment of non-insulin dependent diabetes mellitus. The company provides therapeutic products for diseases, such as diabetes, obesity, oncology, and cardiovascular diseases, as well as for other metabolic disorders. It serves biotechnology and pharmaceutical companies in the Middle East, Africa, Turkey, and Caspian Regions. Newbridge Pharmaceuticals was founded in 2007 and is based in Dubai, the United Arab Emirates.
Management Vice President Business DevelopmentGarrett Vygantas
Dr. Garrett Vygantas joined Burrill & Company in 2006 as a member of the Venture Group and is involved in the sourcing, evaluating and structuring new investment opportunities across the life science spectrum. Garrett is also a member of the Burrill International Group. In 2007 he founded New-Bridge Pharmaceuticals and serves as President & interim CEO. NewBridge is a Dubai-based specialty pharmaceutical company commercializing innovative therapies to treat chronic diseases of increasing incidence (diabetes, obesity, cardiovascular and cancer) in emerging markets of the Middle East, Africa, Turkey and Caspian regions. He serves on the Board of NewBridge and is a Board Observer on Nora Therapeutics, Ikano Therapeutics, ProteoGenix, and NanoVasc.
Before joining Burrill, Garrett was with Genentechs Market Planning Group where he focused on the commercialization and launch of Lucentis for the treatment of age-related macular degeneration.
Chief Executive OfficerJoe Henein
President & CEO at NewBridge Pharmaceuticals
Summary Prior Year RevenueCurrent Year RevenueNext Year Revenue Company AgeEmployeesSub-Industry-3Other BiotechnologyCompany TypeStock ExchangeStock SymbolPrivately-Held--
MENAFN2607201700703403ID1095661253
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.